Medicare GLP-1 Coverage 2026: Does Medicare Cover Ozempic, Wegovy & Zepbound?

For years, seniors with obesity watched younger, commercially-insured patients access revolutionary GLP-1 weight-loss medications while Medicare left them behind. That changed in 2026. A combination of new CMS payment models and expanded Part D coverage rules has made GLP-1 drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) accessible to millions of Medicare beneficiaries for the first time. Here's everything you need to know — including the risks that many articles aren't telling you about.

What Are GLP-1 Drugs and Why Do They Matter?

GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes that were found to produce dramatic weight loss. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Zepbound) work by mimicking gut hormones that regulate appetite and blood sugar, reducing hunger and slowing gastric emptying. Clinical trials have shown average weight loss of 15–22% of body weight — results previously only seen with bariatric surgery.

For seniors with obesity-related conditions — cardiovascular disease, type 2 diabetes, sleep apnea, osteoarthritis — this level of weight loss can be transformative, reducing cardiovascular risk and joint pain significantly. The SELECT trial, published in the New England Journal of Medicine, found that semaglutide reduced major cardiovascular events by 20% in non-diabetic adults with obesity and cardiovascular disease.

The CMS BALANCE Model: What's Actually Changing in 2026

The Center for Medicare & Medicaid Innovation (CMMI) launched the Behavioral Health and Lifestyle Interventions for Chronic Conditions Evaluation (BALANCE) model as a pilot program that expands coverage of anti-obesity medications in select participating plans. Simultaneously, CMS issued guidance clarifying that Medicare Part D plans can cover FDA-approved medications for chronic weight management — which now includes Wegovy and Zepbound — when prescribed for eligible beneficiaries.

This is a significant shift from the long-standing policy that excluded weight-loss drugs from Part D coverage. Not all plans have adopted this coverage, and coverage varies by plan, so you must check your specific Part D plan's formulary.

Who Qualifies for GLP-1 Coverage Under Medicare?

Eligibility criteria for Medicare GLP-1 coverage in 2026 follow the FDA-approved indications for chronic weight management:

• BMI of 30 or higher (classified as obesity), OR
• BMI of 27 or higher with at least one weight-related comorbidity, such as:
  • Type 2 diabetes
  • Hypertension (high blood pressure)
  • High cholesterol/dyslipidemia
  • Cardiovascular disease
  • Sleep apnea
  • Osteoarthritis

Many seniors in the 60–80 age range will meet at least one of these criteria. If you're unsure of your BMI, your doctor can calculate it from your height and weight at your next visit.

What It Costs Under Medicare Part D in 2026

The landmark change in Medicare drug coverage for 2026 is the new $2,000 out-of-pocket cap on Part D drug costs — a provision from the Inflation Reduction Act that takes full effect this year. This means no matter how expensive your medications are, you will pay no more than $2,000 for all covered Part D drugs combined in a calendar year.

For GLP-1 drugs, which carry list prices of $1,000–$1,500/month (approximately $12,000–$18,000/year), this cap is enormously significant. Your actual costs will depend on your plan's tier placement for the specific drug, your income, and whether you've hit the cap already with other medications. Beneficiaries with low income who qualify for Extra Help may pay as little as $0–$11/month.

The Muscle Loss Warning No One Is Talking About

Here's what every senior considering GLP-1 therapy needs to understand: these medications cause significant muscle loss along with fat loss. Research published in the journal Obesity found that 25–40% of total weight lost on semaglutide is lean muscle mass, not fat. For a 70-year-old who loses 30 pounds on Wegovy, that could mean 8–12 pounds of muscle lost — which dramatically increases risk of falls, frailty, and functional decline.

Bone density can also decrease. A 2024 study in JAMA Network Open found meaningful reductions in bone mineral density among older adults taking GLP-1 agonists, raising concerns about fracture risk.

This doesn't mean seniors shouldn't use these medications — for those with severe obesity and cardiovascular risk, the benefits may outweigh the risks. But it absolutely means GLP-1 therapy should be paired with:

• Resistance training (strength training at least 2x/week)
• Adequate protein intake (1.2–1.6g per kg body weight)
• Creatine supplementation, which has strong evidence for preserving muscle mass and strength in older adults

How to Talk to Your Doctor About GLP-1 Coverage

Don't wait for your doctor to bring this up — many physicians aren't yet up to speed on the Medicare coverage changes. Come prepared with these questions:

1. "Do I meet the BMI or comorbidity criteria for GLP-1 therapy?"
2. "Does my Medicare Part D plan cover Wegovy or Zepbound, and if so, what tier?"
3. "What monitoring would you recommend — bone density, muscle mass, labs?"
4. "Can we set up a strength training plan to accompany the medication?"
5. "What's the plan if I need to stop the medication — how do we prevent weight regain?"

Your primary care doctor can prescribe GLP-1 drugs, but you may also ask for a referral to an obesity medicine specialist for a comprehensive management plan.

Alternatives and Complementary Approaches

GLP-1 drugs aren't the only path to weight management and metabolic health improvement in seniors. For those who don't qualify, can't tolerate the medications, or prefer lifestyle-first approaches:

Mediterranean diet consistently shows benefits for cardiovascular health, blood sugar management, and modest weight loss without the side effects. The PREDIMED trial demonstrated a 30% reduction in major cardiovascular events.

Time-restricted eating (eating within an 8–10 hour window) has shown modest but real benefits for metabolic health in several studies.

Resistance training + creatine is genuinely one of the most powerful metabolic interventions available — improving insulin sensitivity, body composition, and functional strength simultaneously, with an excellent safety profile in older adults.

Frequently Asked Questions